The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alieva A.M.

Pirogov Russian National Research Medical University, Moscow, Russia

Baykova I.E.

Pirogov Russian National Research Medical University, Moscow, Russia

Khadzhieva N.Kh.

Clinic of DNA Genetics “MedEstet”, Moscow, Russia

Sultangalieva A.B.

Pirogov Russian National Research Medical University, Moscow, Russia

Elmurzaeva D.A.

Kabardino-Balkarian State University, Nalchik, Russia

Rakhaev A.M.

Kabardino-Balkarian State University, Nalchik, Russia

Nikitin I.G.

Pirogov Russian National Research Medical University, Moscow, Russia

Matrix metalloproteinase 2 as a biological marker in heart failure

Authors:

Alieva A.M., Baykova I.E., Khadzhieva N.Kh., Sultangalieva A.B., Elmurzaeva D.A., Rakhaev A.M., Nikitin I.G.

More about the authors

Journal: Russian Cardiology Bulletin. 2026;21(2): 13‑21

DOI: 10.17116/Cardiobulletin20262102113

Read: 509 times

Contact the author
Table of contents

MATRIX METALLOPROTEINASE 2 AS A BIOLOGICAL MARKER IN HEART FAILURE
MATRIX METALLOPROTEINASE 2 AS A BIOLOGICAL MARKER IN HEART FAILURE

To cite this article:

Alieva AM, Baykova IE, Khadzhieva NKh, Sultangalieva AB, Elmurzaeva DA, Rakhaev AM, Nikitin IG. Matrix metalloproteinase 2 as a biological marker in heart failure. Russian Cardiology Bulletin. 2026;21(2):13‑21. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20262102113

 
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Visceral obesity is a reve­rsible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16
Moni­toring of chro­nic heart failure using transthoracic impe­dance and heart rate variability sensor in patients with cardioverter defi­brillator. Russian Cardiology Bulletin. 2025;(4):48-55
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49
Risk-based approach as an opti­mal patients with chro­nic heart failure and cardiac rhythm diso­rders mana­gement stra­tegy. Russian Journal of Preventive Medi­cine. 2026;(3):29-34
Recu­rrent left ventricular outflow tract obstruction after septal myectomy: analysis of causes and seco­ndary correction. Russian Journal of Cardiology and Cardiovascular Surgery. 2026;(3):57-61
Abstract:

Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.

Keywords:

heart failure
biological markers
matrix metalloproteinase 2

Authors:

Alieva A.M.

Pirogov Russian National Research Medical University, Moscow, Russia

Baykova I.E.

Pirogov Russian National Research Medical University, Moscow, Russia

Khadzhieva N.Kh.

Clinic of DNA Genetics “MedEstet”, Moscow, Russia

Sultangalieva A.B.

Pirogov Russian National Research Medical University, Moscow, Russia

Elmurzaeva D.A.

Kabardino-Balkarian State University, Nalchik, Russia

Rakhaev A.M.

Kabardino-Balkarian State University, Nalchik, Russia

Nikitin I.G.

Pirogov Russian National Research Medical University, Moscow, Russia

Received:

18.11.2024

Accepted:

13.01.2025

Close metadata

References:

  1. Boytsov SA. Chronic heart failure: evolution of etiology, prevalence and mortality over the past 20 years. Terapevticheskii arkhiv. 2022;94(1):5-8. (In Russ.). https://doi.org/10.26442/00403660.2022.01.201317
  2. Alieva AM, Teplova NV, Batov MA, Voronkova KV, Valiev RK, Shnakhova LM, Pinchuk TV, Rakhaev AM, Kalova MR, Nikitin IG. Pentraxin-3 — a promising biological marker in heart failure: literature review. Consilium Medicum. 2022;24(1):53-59. (In Russ.). https://doi.org/10.26442/20751753.2022.1.201382
  3. Alieva AM, Reznik EV, Pinchuk TV, Arakelyan RA, Valiev RK, Rakhaev AM, Tikhomirova AS, Nikitin IG. Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. The Russian Archives of Internal Medicine. 2023;13(1):14-23. (In Russ.). https://doi.org/10.20514/2226-6704-2023-13-1-14-23
  4. Alieva AM, Teplova NV, Kislyakov VA, Voronkova KV, Shnakhova LM, Valiev RK, Rakhaev AM, Elmurzaeva JA, Malkarova DS, Nikitin IG. Biomarkers in cardiology: microRNAs and heart failure. Therapy. 2022;1:60-70. (In Russ.). https://doi.org/10.18565/therapy.2022.1.60-70
  5. Pecherina TB, Barbarash OL. Clinical and prognostic significance of matrix metalloproteinases in patients with myocardial infarction. Fundamental and Clinical Medicine. 2019;4(2):84-94. (In Russ.). https://doi.org/10.23946/2500-0764-2019-4-2-84-94
  6. Wysocka A, Szczygielski J, Kopańska M, Oertel JM, Głowniak A. Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications. International Journal of Molecular Sciences. 2023;24(4):3628. https://doi.org/10.3390/ijms24043628
  7. Trentini A, Manfrinato MC, Castellazzi M, Bellini T. Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases. Journal of Personalized Medicine. 2022;12(8):1196. https://doi.org/10.3390/jpm12081196
  8. Wang Y, Jiao L, Qiang C, Chen C, Shen Z, Ding F, Lv L, Zhu T, Lu Y, Cui X. The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms. Biomedicine & Pharmacotherapy. 2024;171:116116. https://doi.org/10.1016/j.biopha.2023.116116
  9. Hardy E, Hardy-Sosa A, Fernandez-Patron C. MMP-2: is too low as bad as too high in the cardiovascular system? American Journal of Physiology-Heart and Circulatory Physiology. 2018;315(5):H1332-H1340. https://doi.org/10.1152/ajpheart.00198.2018
  10. Gonçalves PR, Nascimento LD, Gerlach RF, Rodrigues KE, Prado AF. Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure. Pharmaceuticals. 2022;15(8):920.  https://doi.org/10.3390/ph15080920
  11. Krzywonos-Zawadzka A, Franczak A, Sawicki G, Bil-Lula I. Mixture of MMP-2, MLC, and NOS Inhibitors Affects NO Metabolism and Protects Heart from Cardiac I/R Injury. Cardiology Research and Practice. 2020; 2020:1561478. https://doi.org/10.1155/2020/1561478
  12. Ribeiro Vitorino T, Ferraz do Prado A, Bruno de Assis Cau S, Rizzi E. MMP-2 and its implications on cardiac function and structure: Interplay with inflammation in hypertension. Biochemical Pharmacology. 2023; 215:115684. https://doi.org/10.1016/j.bcp.2023.115684
  13. Tan R, You Q, Cui J, Wang M, Song N, An K, Lin L, Adu-Amankwaah J, Yuan J, Sun H. Sodium houttuyfonate against cardiac fibrosis attenuates isoproterenol-induced heart failure by binding to MMP2 and p38. Phytomedicine. 2023;109:154590. https://doi.org/10.1016/j.phymed.2022.154590
  14. Maybee DV, Ink NL, Ali MAM. Novel Roles of MT1-MMP and MMP-2: Beyond the Extracellular Milieu. International Journal of Molecular Sciences. 2022;23(17):9513. https://doi.org/10.3390/ijms23179513
  15. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(4):H1847-60.  https://doi.org/10.1152/ajpheart.00434.2006
  16. DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial Matrix Metalloproteinase-2: Inside out and Upside Down. Journal of Molecular and Cellular Cardiology. 2014;77:64—72.  https://doi.org/10.1016/j.yjmcc.2014.09.016
  17. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. Journal of Clinical Investigation. 2005;115:599—609.  https://doi.org/10.1172/JCI22304
  18. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47:711-717.  https://doi.org/10.1161/01.HYP.0000208840.30778.00
  19. Gömöri K, Szabados T, Kenyeres É, Pipis J, Földesi I, Siska A, Dormán G, Ferdinandy P, Görbe A, Bencsik P. Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors. International Journal of Molecular Sciences. 2020;21(19):6990. https://doi.org/10.3390/ijms21196990
  20. Bassiouni W, Valencia R, Mahmud Z, Seubert JM, Schulz R. Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia-reperfusion injury. Basic Research in Cardiology. 2023;118(1):29.  https://doi.org/10.1007/s00395-023-00999-y
  21. Guo C, Ji W, Yang W, Deng Q, Zheng T, Wang Z, Sui W, Zhai C, Yu F, Xi B, Yu X, Xu F, Zhang Q, Zhang W, Kong J, Zhang M, Zhang C. NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post-Myocardial Infarction via Human Antigen R. Advanced Science. 2023;10(30):e2303283. https://doi.org/10.1002/advs.202303283
  22. Tan W, Li X, Zheng S, Li X, Zhang X, Pyle WG, Chen H, Wu J, Sun H, Zou Y, Backx PH, Yang FH. A Porcine Model of Heart Failure with Preserved Ejection Fraction Induced by Chronic Pressure Overload Characterized by Cardiac Fibrosis and Remodeling. Frontiers in Cardiovascular Medicine. 2021;8:677727. https://doi.org/10.3389/fcvm.2021.677727
  23. Pernomian L, Blascke de Mello MM, Parente JM, Sanches-Lopes JM, Tanus-Santos JE, Parreiras E Silva LT, Antunes-Rodrigues J, da Conceição Dos Santos R, Elias LLK, Fabro AT, Silva CAA, Fazan R Jr, de Castro MM. The hydrogen sulfide donor 4-carboxyphenyl-isothiocyanate decreases blood pressure and promotes cardioprotective effect through reduction of oxidative stress and nuclear factor kappa B/matrix metalloproteinase (MMP)-2 axis in hypertension. Life Sciences. 2024;351:122819. https://doi.org/10.1016/j.lfs.2024.122819
  24. Ma Y, Kuang Y, Bo W, Liang Q, Zhu W, Cai M, Tian Z. Exercise Training Alleviates Cardiac Fibrosis through Increasing Fibroblast Growth Factor 21 and Regulating TGF-β1-Smad2/3-MMP2/9 Signaling in Mice with Myocardial Infarction. International Journal of Molecular Sciences. 2021; 22(22):12341. https://doi.org/10.3390/ijms222212341
  25. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. European Journal of Heart Failure. 2004;6(1):41-5.  https://doi.org/10.1016/j.ejheart.2003.05.002
  26. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal. 2005;150:484-487.  https://doi.org/10.1016/j.ahj.2004.11.016
  27. Holm H, Magnusson M, Jujić A, Lagrange J, Bozec E, Lamiral Z, Bresso E, Huttin O, Baudry G, Monzo L, Rossignol P, Zannad F, Girerd N. Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology — the STANISLAS cohort. European Journal of Heart Failure. 2024. https://doi.org/10.1002/ejhf.3411
  28. Gao Y, Bai X, Lu J, Zhang L, Yan X, Huang X, Dai H, Wang Y, Hou L, Wang S, Tian A, Li J. Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine. 2021;8:779282. https://doi.org/10.3389/fcvm.2021.779282
  29. Dattani A, Brady EM, Kanagala P, Stoma S, Parke KS, Marsh AM, Singh A, Arnold JR, Moss AJ, Zhao L, Cvijic ME, Fronheiser M, Du S, Costet P, Schafer P, Carayannopoulos L, Chang CP, Gordon D, Ramirez-Valle F, Jerosch-Herold M, Nelson CP, Squire IB, Ng LL, Gulsin GS, McCann GP. Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers. BMC Cardiovascular Disorders. 2024;24(1):94.  https://doi.org/10.1186/s12872-024-03734-0
  30. Kobayashi M, Ferreira JP, Duarte K, Bresso E, Huttin O, Bozec E, Brunner La Rocca HP, Delles C, Clark AL, Edelmann F, González A, Heymans S, Pellicori P, Petutschnigg J, Verdonschot JAJ, Rossignol P, Cleland JGF, Zannad F, Girerd N; HOMAGE Trial Committees and Investigators. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort. European Journal of Heart Failure. 2024;26(5):1231-1241. https://doi.org/10.1002/ejhf.3202
  31. Täger T, Wiebalck C, Fröhlich H, Corletto A, Katus HA, Frankenstein L. Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure. Clinical Research in Cardiology. 2017;106(12):974-985.  https://doi.org/10.1007/s00392-017-1147-5
  32. Morishita T, Uzui H, Sato Y, Mitsuke Y, Tada H. Associations between cachexia and metalloproteinases, haemodynamics and mortality in heart failure. European Journal of Clinical Investigation. 2021;51(4):e13426. https://doi.org/10.1111/eci.13426
  33. Chuang LP, Pang JS, Lin SW, Hung KC, Hu HC, Kao KC, Wen MS, Chen NH. Elevated serum matrix metalloproteinase-2 levels in heart failure patients with reduced ejection fraction and Cheyne-Stokes respiration. Journal of Clinical Sleep Medicine. 2022;18(5):1365-1373. https://doi.org/10.5664/jcsm.9870
  34. Kayvanpour E, Sedaghat-Hamedani F, Li DT, Miersch T, Weis T, Hoefer I, Frey N, Meder B. Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes. Biomolecules. 2024;14(9):1137. https://doi.org/10.3390/biom14091137
  35. Li S, Zeng X, Wang S, Xie X, Lan J. Association between MMP2 gene polymorphisms and dilated cardiomyopathy in a Chinese Han population. ESC Heart Failure. 2023;10(3):1793-1802. https://doi.org/10.1002/ehf2.14333
  36. Borowiec K, Wozniak O, Wrobel A, Smigielski W, Skrzypczynska-Banasik U, Kowalik E, Lutynska A, Hoffman P, Biernacka EK. A new model for predicting adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Polish Archives of Internal Medicine. 2023;133(7-8):16443. https://doi.org/10.20452/pamw.16443
  37. Ahmed A, Ahmed S, Arvidsson M, Bouzina H, Lundgren J, Rådegran G. Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics. ESC Heart Failure. 2020;7(1):223-234.  https://doi.org/10.1002/ehf2.12560
  38. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: Implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122:2039—2047. https://doi.org/10.1161/CIRCULATIONAHA.109.930222
  39. Andreev DA, Balakin EI, Samoilov AS, Pustovoit VI. The Role of Doxorubicin in the Formation of Cardiotoxicity — Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review). Drug development & registration. 2024;13(1):190-199. (In Russ.). https://doi.org/10.33380/2305-2066-2024-13-1-1508
  40. Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Challa A, Kogan E, Fogacci F, Mikhaleva L, Vandysheva R, Yakubovskaya M, Faggiano A, Carugo S, Urazova O, Jahanbin B, Lesovaya E, Polana S, Kirsanov K, Sattar Y, Trofimenko A, Demura T, Saghazadeh A, Koliakos G, Shafie D, Alizadehasl A, Cicero A, Costabel JP, Biondi-Zoccai G, Ottaviani G, Sarrafzadegan N. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovascular Pathology. 2024; 73:107683. https://doi.org/10.1016/j.carpath.2024.107683
  41. Vitale R, Marzocco S, Popolo A. Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account. International Journal of Molecular Sciences. 2024;25(13):7477. https://doi.org/10.3390/ijms25137477
  42. Dantas D, Pereira AG, Fujimori ASS, Ribeiro APD, de Almeida Silva CCV, Monte MG, Corrêa CR, Fernandes AA, Bazan SGZ, Azevedo PS, Minicucci MF, de Paiva SAR, Zornoff LAM, Polegato BF. Doxycycline Attenuates Doxorubicin-Induced Cardiotoxicity by Improving Myocardial Energy Metabolism in Rats. Journal of Cardiovascular Development and Disease. 2022;9(8):254.  https://doi.org/10.3390/jcdd9080254
  43. Chan BYH, Roczkowsky A, Cho WJ, Poirier M, Sergi C, Keschrumrus V, Churko JM, Granzier H, Schulz R. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling. Cardiovascular Research. 2021;117:188-200.  https://doi.org/10.1093/cvr/cvaa017
  44. Bencsik P, Kupai K, Gorbe A, Kenyeres E, Varga ZV, Paloczi J, Gaspar R, Kovacs L, Weber L, Takacs F, Hajdu I, Fabo G, Cseh S, Barna L, Csont T, Csonka C, Dorman G, Ferdinandy P. Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection. Frontiers in Pharmacology. 2018;9:296.  https://doi.org/10.3389/fphar.2018.00296
  45. Gomori K, Szabados T, Kenyeres E, Pipis J, Foldesi I, Siska A, Dorman G, Ferdinandy P, Gorbe A, Bencsik P. Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors. International Journal of Molecular Sciences. 2020;21:6990. https://doi.org/10.3390/ijms21196990
  46. Kasravi M, Yaghoobi A, Tayebi T, Hojabri M, Taheri AT, Shirzad F, Nooshin BJ, Mazloomnejad R, Ahmadi A, Tehrani FA, Yazdanpanah G, Farjoo MH, Niknejad H. MMP inhibition as a novel strategy for extracellular matrix preservation during whole liver decellularization. Biomaterials Advances. 2024;156:213710. https://doi.org/10.1016/j.bioadv.2023.213710
  47. Blascke de Mello MM, Neves VGO, Parente JM, Pernomian L, Oliveira IS, Pedersoli CA, Awata WMC, Tirapelli CR, Arantes EC, Tostes RCA, Schulz R, Castro MM. Sarcoplasmic reticulum calcium ATPase (SERCA) proteolysis by matrix metalloproteinase-2 contributes to vascular dysfunction in early hypertension. European Journal of Pharmacology. 2024;983:176981. https://doi.org/10.1016/j.ejphar.2024.176981
  48. Parente JM, Blascke de Mello MM, Silva P, Omoto ACM, Pernomian L, Oliveira IS, Mahmud Z, Fazan R Jr, Arantes EC, Schulz R, Castro MM. MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin. Biochemical Pharmacology. 2021;193:114744. https://doi.org/10.1016/j.bcp.2021.114744
  49. Krzywonos-Zawadzka A, Olejnik A, Sawicki G, Bil-Lula I. In Vivo Study on Doxycycline Protective Mechanisms during Myocardial Ischemia Injury in Rats. Biomedicines. 2024;12(3):634.  https://doi.org/10.3390/biomedicines12030634
  50. Cerisano G, Buonamici P, Valenti R, Sciagra R, Raspanti S, Santini A, Carrabba N, Dovellini EV, Romito R, Pupi A, Colonna P, Antoniucci D. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: The TIPTOP trial. European Heart Journal. 2014; 35:184-191.  https://doi.org/10.1093/eurheartj/eht420
  51. Wang LL, Chung JJ, Li EC, Uman S, Atluri P, Burdick JA. Injectable and protease-degradable hydrogel for siRNA sequestration and triggered delivery to the heart. Journal of Controlled Release. 2018;285:152-161.  https://doi.org/10.1016/j.jconrel.2018.07.004
  52. Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Tomita K, Tsurumi M, Matsushita M, Mizuno K. Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure. Journal of Cardiology. 2012;59:374-382.  https://doi.org/10.1016/j.jjcc.2012.01.009
  53. Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research. 2016;107:1-18.  https://doi.org/10.1016/j.phrs.2016.02.012
  54. Skrzypiec-Spring M, Sapa-Wojciechowska A, Rak-Pasikowska A, Kaczorowski M, Bil-Lula I, Hałoń A, Szeląg A. The Protective Effect of Simvastatin on the Systolic Function of the Heart in the Model of Acute Ischemia and Reperfusion Is Due to Inhibition of the RhoA Pathway and Independent of Reduction of MMP-2 Activity. Biomolecules. 2022;12(9):1291. https://doi.org/10.3390/biom12091291
  55. Gong W, Ma Y, Li A, Shi H, Nie S. Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction. Cardiovascular Therapeutics. 2018; 36:e12460. https://doi.org/10.1111/1755-5922.12460
  56. Skrzypiec-Spring M, Urbaniak J, Sapa-Wojciechowska A, Pietkiewicz J, Orda A, Karolko B, Danielewicz R, Bil-Lula I, Wozniak M, Schulz R, Szelag A. Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol. Pharmaceuticals. 2021;14:1276. https://doi.org/10.3390/ph14121276
  57. Mendes AS, Blascke de Mello MM, Parente JM, Omoto ACM, Neto-Neves EM, Fazan R Jr, Tanus-Santos JE, Castro MM. Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. Life Sciences. 2020; 244:117153. https://doi.org/10.1016/j.lfs.2019.117153
  58. Wee LE, Tan WZ, Chow JY, Lim JT, Chiew C, Chia PY, Ng LC, Amanullah MR, Yap J, Yeo KK, Yee Chan MY, Hausenloy DJ, Leo YS, Lye DC, Tan KB. Cardiovascular complications in acute dengue infection: a population-based cohort study. Lancet Reg Health West Pac. 2025;64:101713. https://doi.org/10.1016/j.lanwpc.2025.101713
  59. Niranjan R, Vidhyapriya P, Murugasamy V, Muthukumaravel S, Kumar A. Effects of dengue virus type-2 serotype (DENV-2) on the expression profile of matrix metalloproteinases in THP-1, monocyte cells and their roles in endothelial dysfunctions: protective effect of atorvastatin. Front Cell Infect Microbiol. 2025;15:1632634. https://doi.org/10.3389/fcimb.2025.1632634
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.